We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intellia Therapeutics Inc | NASDAQ:NTLA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.18 | 5.07% | 24.45 | 4.90 | 28.97 | 24.99 | 23.42 | 24.44 | 1,294,988 | 05:00:07 |
From May 2021 to May 2024
By Colin Kellaher
Intellia Therapeutics Inc. on Thursday said the U.S. Food and Drug Administration has accepted its investigational new drug application for NTLA-5001 in acute myeloid leukemia, a cancer of the blood and bone marrow.
The Cambridge, Mass., clinical-stage genome-editing company said NTLA-5001 would be its first ex-vivo candidate using its proprietary cell-engineering process for the treatment of cancer to enter clinical studies.
Intellia said it plans to begin patient screening by the end of the year for a Phase 1/2a study evaluating NTLA-5001 in adults with persistent or recurrent acute myeloid leukemia who have previously received first-line therapy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 16, 2021 08:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Intellia Therapeutics Chart |
1 Month Intellia Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
